tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 307 are a BUY (84.57%), 55 are a HOLD (15.15%), 1 are a SELL (0.28%).
Analyst Robyn Karnauskas, carries an average stock price target met ratio of 53.73% that have a potential upside of 41.57% achieved within 362 days. Previously, Robyn Karnauskas worked at TRUIST.
Robyn Karnauskas’s has documented 739 price targets and ratings displayed on 46 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on TRML, Tourmaline Bio at 10-Sep-2025.
Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$280
$52.34 (22.99%)
$200
1 months ago
(13-Nov-2025)
5/6 (83.33%)
$46.77 (20.05%)
236
Buy
$237
$9.34 (4.10%)
$188
1 months 9 days ago
(04-Nov-2025)
2/3 (66.67%)
$18.96 (8.70%)
109
Hold
$235
$7.34 (3.22%)
$251
1 months 10 days ago
(03-Nov-2025)
16/17 (94.12%)
$16.96 (7.78%)
282
Buy
$260
$32.34 (14.21%)
$235
1 months 10 days ago
(03-Nov-2025)
14/15 (93.33%)
$41.96 (19.24%)
483
Buy
$242
$14.34 (6.30%)
$216
1 months 23 days ago
(20-Oct-2025)
27/28 (96.43%)
$9.94 (4.28%)
437
Which stock is Robyn Karnauskas is most bullish on?
What Year was the first public recommendation made by Robyn Karnauskas?
